Barclays Portfolio holdings
Barclays PLC, founded in 1690 by goldsmith bankers in London, is a British multinational financial institution headquartered in London, operating as one of the world’s oldest banks with a significant presence in investment banking, retail banking, and wealth management. Managing billions in assets, Barclays serves millions of customers globally through its retail arm (notably in the UK) and its investment banking division, which excels in trading, mergers and acquisitions, and capital markets, competing with Wall Street giants. The bank has navigated challenges like the 2008 financial crisis—opting for private funding over a government bailout—and has since focused on restructuring, digital innovation, and sustainable finance initiatives. With a rich history and a modern global footprint, Barclays remains a key player in both UK and international financial markets.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
CRH
CRH
|
+$2.05B |
| 2 |
Texas Instruments
TXN
|
+$1.69B |
| 3 |
NVIDIA
NVDA
|
+$1.36B |
| 4 |
Starbucks
SBUX
|
+$1.2B |
| 5 |
State Street Consumer Discretionary Select Sector SPDR ETF
XLY
|
+$949M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Apple
AAPL
|
+$2.77B |
| 2 |
Microsoft
MSFT
|
+$1.3B |
| 3 |
Alphabet (Google) Class C
GOOG
|
+$1.22B |
| 4 |
iShares US Real Estate ETF
IYR
|
+$1.11B |
| 5 |
Procter & Gamble
PG
|
+$915M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 22.33% |
| 2 | Consumer Discretionary | 7.25% |
| 3 | Financials | 7.18% |
| 4 | Communication Services | 6.16% |
| 5 | Healthcare | 5.91% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
4101
Culp Inc
CULP
$46.2M
| $43.3K | ﹤0.01% |
9,658
| – | – |
|
4102
Perma-Fix Environmental Services
PESI
$361M
| $43.2K | ﹤0.01% |
+4,262
| New | +$47.2K |
|
4103
908 Devices
MASS
$339M
| $43.1K | ﹤0.01% |
8,361
-7,207
| -46% | -$43.5K |
|
4104
FibroBiologics
FBLG
$4.5M
| $43K | ﹤0.01% |
+431
| New | +$82.2K |
|
|
TGB
4105
Trekor Metals
TGB
$2.45B
| $42.9K | ﹤0.01% |
17,500
-49,622
| -74% | -$126K |
|
4106
Cognyte Software
CGNT
$667M
| $42.8K | ﹤0.01% |
5,600
+3,405
| +155% | +$25.4K |
|
|
MRNS
4107
DELISTED
Marinus Pharmaceuticals, Inc
MRNS
| $42.6K | ﹤0.01% |
36,399
-39,430
| -52% | -$98.7K |
|
4108
Xenon Pharmaceuticals
XENE
$5.94B
| $42.5K | ﹤0.01% |
1,090
-11,464
| -91% | -$458K |
|
|
SCPH
4109
DELISTED
scPharmaceuticals
SCPH
| $42.4K | ﹤0.01% |
9,742
-10,562
| -52% | -$46.4K |
|
4110
MediWound
MDWD
$182M
| $42.1K | ﹤0.01% |
+2,714
| New | +$44.9K |
|
4111
Latham Group
SWIM
$650M
| $42K | ﹤0.01% |
13,860
-13,074
| -49% | -$45.6K |
|
4112
Energy Vault
NRGV
$531M
| $42K | ﹤0.01% |
44,209
-33,199
| -43% | -$41.2K |
|
4113
ProShares Ultra VIX Short-Term Futures ETF
UVXY
$242M
| $42K | ﹤0.01% |
357
+300
| +526% | +$43.8K |
|
|
CTNM
4114
Contineum Therapeutics
CTNM
$587M
| $42K | ﹤0.01% |
+2,383
| New | +$38.4K |
|
4115
Core Molding Technologies
CMT
$207M
| $41.8K | ﹤0.01% |
2,624
-2,483
| -49% | -$45.4K |
|
4116
iShares S&P Small-Cap 600 Value ETF
IJS
$8.27B
| $41.8K | ﹤0.01% |
430
| – | – |
|
4117
State Street Blackstone Senior Loan ETF
SRLN
$5.31B
| $41.8K | ﹤0.01% |
1,000
| – | – |
|
4118
BlackSky Technology
BKSY
$958M
| $41.8K | ﹤0.01% |
4,882
-5,955
| -55% | -$55.8K |
|
|
MOND
4119
DELISTED
Mondee Holdings, Inc. Class A Common Stock
MOND
| $41.8K | ﹤0.01% |
17,396
-15,245
| -47% | -$34K |
|
4120
Candel Therapeutics
CADL
$720M
| $41.6K | ﹤0.01% |
+6,717
| New | +$50.4K |
|
4121
NACCO Industries
NC
$361M
| $41.6K | ﹤0.01% |
1,505
-1,470
| -49% | -$44.7K |
|
4122
VEON
VEON
$3.66B
| $41.5K | ﹤0.01% |
1,600
| – | – |
|
4123
Protalix BioTherapeutics
PLX
$198M
| $41.5K | ﹤0.01% |
35,427
-47,007
| -57% | -$55.5K |
|
4124
Harvard Bioscience
HBIO
$27.1M
| $41.3K | ﹤0.01% |
1,451
-1,415
| -49% | -$49.6K |
|
|
GREK
4125
Global X MSCI Greece ETF
GREK
$315M
| $41.3K | ﹤0.01% |
1,039
| – | – |
|
Similar funds
Barclays's Q2 2024 Portfolio in Review
As of Q2 2024, Barclays held 5,455 positions worth $327B, up 14% from $288B the previous quarter. Its ten largest holdings account for 42% of the portfolio.
Barclays deployed $29.4B of net new capital in Q2 2024, opening 406 new positions and adding to 1,053 existing holdings. Its largest new stake was Ferrovial N.V. Ordinary Shares: 4,837,593 shares worth $186M.
By sector, the portfolio is most concentrated in Technology at 22% of assets, down from 24% a quarter earlier, followed by Consumer Discretionary and Financials.
On the sell side, the largest reduction was Apple, an estimated $2.77B trimmed.
- Barclays's largest Q2 2024 buy was Ferrovial N.V. Ordinary Shares: 4,837,593 shares worth $186M.
- Barclays added most to CRH in Q2 2024, an estimated $2.05B increase.
- Barclays's biggest Q2 2024 reduction was Apple, cutting an estimated $2.77B.
- Barclays fully exited Pioneer Natural Resource Co. in Q2 2024, selling an estimated $212M.
- Barclays's ten largest holdings make up 42% of its $327B portfolio in Q2 2024.
- Barclays opened 406 new positions and closed 646 in Q2 2024.
- Barclays's portfolio value rose 14% quarter-over-quarter to $327B.
Based on Barclays's 13F filing for Q2 2024, filed 14 Aug 2024.